BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 17477358)

  • 1. Selective cyclooxygenase-2 inhibition suppresses basic fibroblast growth factor expression in human esophageal adenocarcinoma.
    Baguma-Nibasheka M; Barclay C; Li AW; Geldenhuys L; Porter GA; Blay J; Casson AG; Murphy PR
    Mol Carcinog; 2007 Dec; 46(12):971-80. PubMed ID: 17477358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells.
    Souza RF; Shewmake K; Beer DG; Cryer B; Spechler SJ
    Cancer Res; 2000 Oct; 60(20):5767-72. PubMed ID: 11059772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific COX-2 inhibitor, NS-398, suppresses cellular proliferation and induces apoptosis in human hepatocellular carcinoma cells.
    Cheng AS; Chan HL; Leung WK; Wong N; Johnson PJ; Sung JJ
    Int J Oncol; 2003 Jul; 23(1):113-9. PubMed ID: 12792783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms.
    Deasy BM; O'Sullivan-Coyne G; O'Donovan TR; McKenna SL; O'Sullivan GC
    Cancer Lett; 2007 Oct; 256(2):246-58. PubMed ID: 17707579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.
    Bae SH; Jung ES; Park YM; Kim BS; Kim BK; Kim DG; Ryu WS
    Clin Cancer Res; 2001 May; 7(5):1410-8. PubMed ID: 11350912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibited proliferation of cyclooxygenase-2 expressing human hepatoma cells by NS-398, a selective COX-2 inhibitor.
    Hu KQ; Yu CH; Mineyama Y; McCracken JD; Hillebrand DJ; Hasan M
    Int J Oncol; 2003 Apr; 22(4):757-63. PubMed ID: 12632065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of growth inhibitory effects of cyclooxygenase-2 inhibitor-NS398 on cancer cells.
    Li S; Tong Q; Zhang W; Wang Q; Chen Z; Wu Q
    Cancer Invest; 2008 May; 26(4):333-7. PubMed ID: 18443952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis.
    Abdalla SI; Lao-Sirieix P; Novelli MR; Lovat LB; Sanderson IR; Fitzgerald RC
    Clin Cancer Res; 2004 Jul; 10(14):4784-92. PubMed ID: 15269153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest.
    Cheong E; Ivory K; Doleman J; Parker ML; Rhodes M; Johnson IT
    Carcinogenesis; 2004 Oct; 25(10):1945-52. PubMed ID: 15155531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of selective cyclooxygenase-2 inhibitor NS-398 on 5-fluorouracil chemotherapy and progression of colon cells: an experimental study].
    Zhang YC; Wang S; Zhang H; Ye YJ; Liang B; Cui ZR
    Zhonghua Yi Xue Za Zhi; 2004 Apr; 84(7):583-6. PubMed ID: 15144595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Spinella F; Rosanò L; Di Castro V; Nicotra MR; Natali PG; Bagnato A
    Clin Cancer Res; 2004 Jul; 10(14):4670-9. PubMed ID: 15269139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NS-398 inhibits tumor growth and liver metastasis of colon cancer through induction of apoptosis and suppression of the plasminogen activation system in a mouse model.
    Nishikawa M; Stapleton PP; Freeman TA; Gaughan JP; Matsuda T; Daly JM
    J Am Coll Surg; 2004 Sep; 199(3):428-35. PubMed ID: 15325613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclooxygenase-2 inhibitor NS398 enhances antitumor effect of irradiation on hormone refractory human prostate carcinoma cells.
    Wen B; Deutsch E; Eschwege P; De Crevoisier R; Nasr E; Eschwege F; Bourhis J
    J Urol; 2003 Nov; 170(5):2036-9. PubMed ID: 14532848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro(1).
    Vona-Davis L; Riggs DR; Jackson BJ; McFadden DW
    J Surg Res; 2004 Jun; 119(2):143-8. PubMed ID: 15145696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398.
    Yu HP; Shi LY; Lu WH; Su YH; Li YY; Xu SQ
    J Gastroenterol Hepatol; 2004 Jun; 19(6):638-42. PubMed ID: 15151617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of selective PGE2 receptor antagonists in esophageal adenocarcinoma cells derived from Barrett's esophagus.
    Piazuelo E; Jiménez P; Strunk M; Santander S; García A; Esteva F; Lanas A
    Prostaglandins Other Lipid Mediat; 2006 Dec; 81(3-4):150-61. PubMed ID: 17085323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statins inhibit proliferation and induce apoptosis in Barrett's esophageal adenocarcinoma cells.
    Ogunwobi OO; Beales IL
    Am J Gastroenterol; 2008 Apr; 103(4):825-37. PubMed ID: 18371146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
    Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
    Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of poor survival by cyclooxygenase-2 in patients with T4 nasopharyngeal cancer treated by radiation therapy: clinical and in vitro studies.
    Chen WC; McBride WH; Chen SM; Lee KF; Hwang TZ; Jung SM; Shau H; Liao SK; Hong JH; Chen MF
    Head Neck; 2005 Jun; 27(6):503-12. PubMed ID: 15772955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase isozymes are expressed in human myeloma cells but not involved in anti-proliferative effect of cyclooxygenase inhibitors.
    Ding J; Tsuboi K; Hoshikawa H; Goto R; Mori N; Katsukawa M; Hiraki E; Yamamoto S; Abe M; Ueda N
    Mol Carcinog; 2006 Apr; 45(4):250-9. PubMed ID: 16385588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.